Table 1.
Baseline variables before and after active and non-active chemotherapy groups propensity score matching.
| Characteristic | Non-Matched | Pair Matched | Standardized Mean Difference | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Active Chemo. n = 431 | Non-Active Chemo. n = 250 | p | Active Chemo. n = 246 | Non-Active Chemo. n = 246 | p | All | Region | Matched | |
| Age | 0.0182 | 0.9893 | |||||||
| <50 years | 121 (28.1) | 46 (18.4) | 49 (19.9) | 46 (18.7) | 0.23058 | 0.19103 | 0.02907 | ||
| 50 to 64 years | 172 (39.9) | 102 (40.8) | 99 (40.2) | 101 (41.1) | −0.01820 | −0.00805 | −0.01657 | ||
| 65 to 79 years | 122 (28.3) | 93 (37.2) | 89 (36.2) | 90 (36.6) | −0.19036 | −0.16575 | −0.00870 | ||
| ≥80 years | 16 (3.7) | 9 (3.6) | 9 (3.7) | 9 (3.7) | 0.00598 | 0.00661 | 0.00000 | ||
| Sex | 0.1849 | 0.7183 | −0.10541 | −0.10407 | 0.03268 | ||||
| Male | 186 (43.2) | 121 (48.4) | 122 (49.6) | 118 (48) | |||||
| Female | 245 (56.8) | 129 (51.6) | 124 (50.4) | 128 (52) | |||||
| Comorbidities | |||||||||
| Heart Disease | 83 (19.3) | 60 (24) | 0.1430 | 60 (24.4) | 57 (23.2) | 0.7507 | −0.11538 | −0.08634 | 0.02967 |
| Diabetes | 66 (15.3) | 38 (15.2) | 0.9684 | 38 (15.5) | 38 (15.5) | 1.0000 | 0.00315 | −0.00225 | 0.00000 |
| Neurologic disease | 5 (1.2) | 8 (3.2) | 0.0608 | 5 (2) | 6 (2.4) | 0.7604 | −0.14003 | −0.08629 | −0.02790 |
| Chronic lung disease | 17 (3.9) | 12 (4.8) | 0.5940 | 11 (4.5) | 12 (4.9) | 0.8309 | −0.04186 | −0.04203 | −0.01988 |
| Nephropathy | 23 (5.3) | 16 (6.4) | 0.5648 | 15 (6.1) | 15 (6.1) | 1.0000 | −0.04526 | −0.02810 | 0.00000 |
| Critical Presentation | 97 (22.5) | 61 (24.4) | 0.5724 | 59 (24) | 61 (24.8) | 0.8337 | −0.04472 | −0.05520 | −0.01919 |
| Southeast | 281 (65.2) | 138 (55.2) | 0.0097 | 138 (56.1) | 137 (55.7) | 0.9277 | 0.20531 | 0.18656 | 0.00835 |
| Clinical Stage | 0.0747 | 0.9835 | |||||||
| I/II | 64 (14.9) | 42 (16.8) | 41 (16.7) | 42 (17.1) | 0.01846 | 0.02824 | −0.03477 | ||
| III/IV | 272 (63.1) | 172 (68.8) | 170 (69.1) | 168 (68.3) | 0.12211 | 0.09351 | 0.00000 | ||
| Unknown | 27 (6.3) | 7 (2.8) | 8 (3.3) | 7 (2.9) | −0.16690 | −0.14763 | −0.01958 | ||
| Other | 68 (15.8) | 29 (11.6) | 27 (11) | 29 (11.8) | −0.12157 | −0.09036 | 0.02366 | ||
| Mult. Drug Regimen | 237 (55) | 132 (52.8) | 0.5806 | 135 (54.9) | 130 (52.9) | 0.6511 | −0.04391 | −0.03066 | −0.04078 |
| Drug Class | |||||||||
| Anti-Metabolic | 169 (39.2) | 96 (38.4) | 0.8342 | 97 (39.4) | 94 (38.2) | 0.7814 | 0.01665 | 0.00663 | 0.02503 |
| Microtubule inhib. | 153 (35.5) | 86 (34.4) | 0.7721 | 82 (33.3) | 84 (34.2) | 0.8488 | 0.02305 | 0.01766 | −0.01705 |
| Alkylating | 115 (26.7) | 53 (21.2) | 0.1097 | 56 (22.8) | 53 (21.5) | 0.7447 | 0.12874 | 0.11029 | 0.02864 |
| Cisplatin | 186 (43.2) | 127 (50.8) | 0.0537 | 127 (51.6) | 125 (50.8) | 0.8568 | −0.15362 | −0.14223 | 0.01634 |
| Type 1 topois. inhib. | 36 (8.4) | 10 (4) | 0.0291 | 13 (5.3) | 10 (4.1) | 0.5217 | 0.18156 | 0.11641 | 0.05087 |
| Type 2 topois. inhib. | 94 (21.8) | 40 (16) | 0.0660 | 40 (16.3) | 40 (16.3) | 1.0000 | 0.14879 | 0.11031 | 0.00000 |
| Treatment | 0.0077 | 0.4682 | |||||||
| Palliative 1st Line | 193 (44.8) | 105 (42) | 119 (48.4) | 103 (41.9) | −0.05602 | −0.07571 | −0.13108 | ||
| Palliative 2nd Line | 36 (8.4) | 22 (8.8) | 16 (6.5) | 22 (8.9) | 0.01595 | 0.02385 | 0.08697 | ||
| Hematological cancer | 111 (25.8) | 44 (17.6) | 41 (16.7) | 44 (17.9) | −0.25943 | −0.21717 | −0.02354 | ||
| Neoadj./Definit./Adjuv. | 91 (21.1) | 79 (31.6) | 70 (28.5) | 77 (31.3) | 0.23933 | 0.22339 | 0.06494 | ||
| Primary Site | 0.0694 | 0.9995 | |||||||
| GI | 121 (28.1) | 78 (31.2) | 83 (33.7) | 78 (31.7) | −0.06849 | −0.08101 | 0.00894 | ||
| Head and Neck | 18 (4.2) | 17 (6.8) | 15 (6.1) | 16 (6.5) | −0.11539 | −0.10312 | −0.01795 | ||
| Lung | 30 (7) | 21 (8.4) | 17 (6.9) | 21 (8.5) | −0.05408 | −0.04458 | −0.04600 | ||
| Others | 15 (3.5) | 14 (5.6) | 14 (5.7) | 12 (4.9) | −0.10195 | −0.06780 | 0.00000 | ||
| Breast | 66 (15.3) | 24 (9.6) | 25 (10.2) | 24 (9.8) | 0.17366 | 0.16172 | 0.06203 | ||
| Gynecological | 42 (9.7) | 33 (13.2) | 33 (13.4) | 32 (13) | −0.10858 | −0.10351 | −0.02565 | ||
| Prostate | 9 (2.1) | 8 (3.2) | 7 (2.9) | 8 (3.3) | −0.06934 | −0.07311 | 0.00000 | ||
| Cent. Nervous Syst. | 8 (1.9) | 4 (1.6) | 4 (1.6) | 4 (1.6) | 0.01966 | 0.01748 | 0.00000 | ||
| Hematologic | 111 (25.8) | 44 (17.6) | 41 (16.7) | 44 (17.9) | 0.19887 | 0.19157 | 0.00995 | ||
| Sarcomas | 11 (2.6) | 7 (2.8) | 7 (2.9) | 7 (2.9) | −0.01535 | −0.01853 | −0.02529 | ||
| Logit Prop. Score | 0.57261 | 0.48064 | 0.06873 | ||||||
| Outcome | 0.0141 | 0.3322 | |||||||
| Hospital Discharge | 166 (38.5) | 73 (29.2) | 83 (33.9) | 73 (29.8) | |||||
| Death | 265 (61.5) | 177 (70.8) | 162 (66.1) | 172 (70.2) | |||||
Abbreviations: Adjuv: Adjuvant; Cent.: Central; Definit: Definitive; GI: Gastrointestinal; Inhib: Inhibitor; Mult.: Multiple; Neoadj: Neoadjuvant; Prop: Propensity; Syst: System; Topois: Topoisomerase.